SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES
SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrentos COVID-19 therapeutic product candidates.
- SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrentos COVID-19 therapeutic product candidates.
- Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases.
- UTMB is an institution in the University of Texas System and a member of the Texas Medical Center.
- Forward-looking statements include statements regarding the preclinical testing of Sorrentos COVID-19 therapeutic product candidates; the safety and efficacy of Sorrentos COVID-19 therapeutic product candidates; the therapeutic potential of Sorrentos COVID-19 therapeutic product candidates for SARS-CoV-2 and COVID-19 disease; and Sorrentos potential position in the vaccine industry.